Novavax Inc (NASDAQ:NVAX) announced it will present on its lead COVID-19 vaccine candidate at the 2020 World Vaccine Congress Washington scheduled for this week.
It will also present its influenza and respiratory syncytial virus jabs, while the main focus will be to share expertise and the latest research related to the pandemic and vaccine development to address global health.
The US firm is set to start late-stage trials for NVX-CoV2373 in the UK, enrolling up to 10,000 participants aged 18-84 over the next six weeks, with half receiving the formulation and half receiving a placebo.
Up to 400 volunteers will receive both Novavax’s candidate and a seasonal flu vaccine to see if the combination works.
Data for from the Phase II of clinical trials are expected in the fourth quarter of 2020.
J&J said last week a single dose of its formulation produced a strong immune response in phase II of trials.